Form 4 for COAG Hemab Therapeutics Holdings, Inc.
Accepted 2026-05-04 16:20:06 ET · period of report 2026-01-29 · accession 0001193125-26-204048 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2026-05-04 16:20 | 2026-05-04 | COAG | MARAGANORE JOHN | Dir | C - Cnv Deriv | — | +35.9K | 35.9K | New | — |
| D | 2026-05-04 16:20 | 2026-01-29 | COAG | MARAGANORE JOHN | Dir | A - Grant | $0.00 | +107.3K | 107.3K | New | $0 |
| DM | 2026-05-04 16:20 | 2026-05-04 | COAG | MARAGANORE JOHN | Dir | C - Cnv Deriv | $0.00 | -1,634 | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-05-04 | C | A | 17,974 | — | 17,974 | D | — | — | (F1) The warrant was granted on January 29, 2026. The shares underlying the warrant vest over three years in equal monthly installments from January 1, 2026 through January 1, 2029. |
| 2 | Common | Common Stock | 2026-05-04 | C | A | 17,974 | — | 35,948 | D | — | — | (F1) The warrant was granted on January 29, 2026. The shares underlying the warrant vest over three years in equal monthly installments from January 1, 2026 through January 1, 2029. |
| 3 | Derivative | Warrants (Right to Buy) | 2026-01-29 | A | A | 107,338 | $0.00 | 107,338 | D | $6.00 · — to 2036-01-28 | 107,338 Common Stock | (F1) The warrant was granted on January 29, 2026. The shares underlying the warrant vest over three years in equal monthly installments from January 1, 2026 through January 1, 2029. |
| 4 | Derivative | Series B Preferred Stock | 2026-05-04 | C | D | 817 | $0.00 | 0 | D | — · — to — | 17,974 Common Stock | (F1) The warrant was granted on January 29, 2026. The shares underlying the warrant vest over three years in equal monthly installments from January 1, 2026 through January 1, 2029. (F2) Each share of Series B Preferred Stock and Series C Preferred Stock converted into 22 shares of common stock without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. (F2) Each share of Series B Preferred Stock and Series C Preferred Stock converted into 22 shares of common stock without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. |
| 5 | Derivative | Series C Preferred Stock | 2026-05-04 | C | D | 817 | $0.00 | 0 | D | — · — to — | 17,974 Common Stock | (F1) The warrant was granted on January 29, 2026. The shares underlying the warrant vest over three years in equal monthly installments from January 1, 2026 through January 1, 2029. (F2) Each share of Series B Preferred Stock and Series C Preferred Stock converted into 22 shares of common stock without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. (F2) Each share of Series B Preferred Stock and Series C Preferred Stock converted into 22 shares of common stock without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. |